Document is current
Any future updates will be listed below
-
Authors
Sadagopan, Ananthan https://orcid.org/0000-0001-6306-4907
Carson, Maximilian
Zamurs, Eriks J. https://orcid.org/0009-0007-4974-8668
Garaffo, Nicholas
Chang, Heng-Jui
Schreiber, Stuart L. https://orcid.org/0000-0003-1922-7558
Meyerson, Matthew https://orcid.org/0000-0002-9133-8108
Gibson, William J. https://orcid.org/0000-0003-3159-8175
-
Funding
Funding for this research was provided by:
Svenson Fellowship Lubin Scholar Award Briger Foundation for Oncology Research Award
Hertz Foundation
Herchel Smith Graduate Fellowship
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA217848, R35CA197568)
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 17 September 2025
First Online: 3 November 2025
Competing interests
: A patent application naming A.S., W.J.G. and M.M. as inventors has been filed by the Broad Institute covering aspects of this work. W.J.G. is on the scientific advisory board and has received consulting fees from Esperion therapeutics and consulting fees from Belharra therapeutics, Boston Clinical Research Institute, Faze Medicines, ImmPACT-Bio and nference. M.M. reports consultant, advisory board and equity for DelveBio and Isabl, research funding from Janssen and Bayer Pharmaceuticals, equity in Bayer and patents licensed to LabCorp and Bayer. S.L.S. is the founding CEO of Arena BioWorks, is a shareholder and serves on the Board of Directors of Kojin Therapeutics, is a shareholder and advises Jnana Therapeutics, Kisbee Therapeutics, Belharra Therapeutics, Magnet Biomedicine, Exo Therapeutics, Eikonizo Therapeutics and Replay Bio, advises Vividion Therapeutics, Eisai, Ono Pharma Foundation and F-Prime Capital Partners and is a Novartis Faculty Scholar. Except for the patent application, competing interests listed above are outside the submitted work. The other authors declare no competing interests.
